{"entity":{"id":"paper-c-etac-one-year-risk-cancer-prev-res-2021","kind":"paper","name":"Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk","aka":[],"tldr":"Datar Cancer Genetics followed people without symptoms for a year after its tumour-cell-cluster blood test and reported that those with a positive result were far more likely to be diagnosed with cancer.","summary":"Ranade and colleagues (with Datar Cancer Genetics, Nashik) report one-year follow-up of the asymptomatic cohort from the company's earlier work (16,134 people, including 10,625 asymptomatic, among whom C-ETACs were found in 3.6%). People with detectable circulating ensembles of tumour-associated cells had a 230-fold higher one-year cancer risk than those without (P < 0.00001). In 4,419 symptomatic people later confirmed to have cancer, C-ETACs were detected in 4,101 (92.8%).","asOf":"2026-11-03","links":[{"label":"Cancer Prevention Research 2021","url":"https://doi.org/10.1158/1940-6207.CAPR-20-0322"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/32958586/"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["mced","ctc-capture"],"targets":[],"drugs":["trucheck-intelli"],"companies":["datar-cancer-genetics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-prevention-research"],"dependsOn":[],"notes":[],"journal":"Cancer Prevention Research","year":2021,"doi":"10.1158/1940-6207.CAPR-20-0322","pmid":"32958586","authors":"Ranade A, Bhatt A, Page R, Limaye S, et al.","paperType":"observational","findings":["C-ETAC-positive asymptomatic people: 230-fold higher one-year cancer risk.","C-ETACs detected in 92.8% of 4,419 symptomatic people with confirmed cancer."],"whatItMeans":"A relative risk does not say what share of positive results turned out to be cancer; with about 3.6% of people without symptoms testing positive, most positives would still not be cancer in a screening population.","caveats":["The abstract gives no positive predictive value or count of cancers among positives.","Datar Cancer Genetics staff among authors."],"changedPractice":false},"route":"/key-papers/paper-c-etac-one-year-risk-cancer-prev-res-2021/","neighbours":{"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"ctc-capture","kind":"technology","name":"Circulating tumour cell capture","route":"/technologies/ctc-capture/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"drug":[{"id":"trucheck-intelli","kind":"drug","name":"Trucheck Intelli","route":"/drugs/trucheck-intelli/"}],"company":[{"id":"datar-cancer-genetics","kind":"company","name":"Datar Cancer Genetics","route":"/companies/datar-cancer-genetics/"}],"journal":[{"id":"cancer-prevention-research","kind":"journal","name":"Cancer prevention research","route":"/journals/cancer-prevention-research/"}]}}